Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991;41(3):263-5.
doi: 10.1007/BF00315441.

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

L S Hermann  1 , J E Karlsson, A Sjöstrand
Affiliations
Clinical Trial

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

L S Hermann et al. Eur J Clin Pharmacol. 1991.

Abstract

Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year. The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total- and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P less than 0.05). No serious adverse effects were observed. The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.

PubMed Disclaimer

References

    1. Diabet Med. 1988 Oct;5(7):653-8 - PubMed
    1. J R Soc Med. 1989 Feb;82(2):93-4 - PubMed
    1. Diabetologia. 1982 Dec;23(6):507-10 - PubMed
    1. N Engl J Med. 1989 Nov 2;321(18):1231-45 - PubMed
    1. Diabetes Care. 1990 Jan;13(1):1-8 - PubMed

MeSH terms

LinkOut - more resources